Page 137 - 2021_10-Haematologica-web

B-cell evolutionary patterns in NLPHL
Funding
Financial support from the Deutsche Forschungsgemeinschaft (DFG BI 1711/4-1 to MB and DFG HA 6145/3-1 to SH) is acknowledged.
Data-sharing statement
The sequence dataset reported in this study has been deposited in the European Nucleotide Archive (ENA) ID: PRJEB37464.
References
1. Saarinen S, Pukkala E, Vahteristo P, Mäkinen MJ, Franssila K, Aaltonen LA. High familial risk in nodular lymphocyte- predominant Hodgkin lymphoma. J Clin Oncol. 2013;31(7):938-943.
2. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte pre- dominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abun- dant lymphocytes. Blood. 2000;96(5):1889- 1899.
3. Hartmann S, Eichenauer DA, Plütschow A, et al. The prognostic impact of variant his- tology in nodular lymphocyte-predomi- nant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013;122(26):4246-4252.
4. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (Revised 4th edition). Lyon: International Agency for Research on Cancer; 2017.
5.Piccaluga PP, Agostinelli C, Gazzola A, et al. Pathobiology of Hodgkin lymphoma. Adv Hematol. 2011;2011:920898.
6. Prakash S, Fountaine T, Raffeld M, Jaffe ES, Pittaluga S. IgD positive L&H cells identify a unique subset of nodular lymphocyte pre- dominant Hodgkin lymphoma. Am J Surg Pathol. 2006;30(5):585-592.
7. Schmid C, Sargent C, Isaacson PG. L and H cells of nodular lymphocyte predominant Hodgkin's disease show immunoglobulin light-chain restriction. Am J Pathol. 1991;139(6):1281-1289.
8. Hartmann S, Eichenauer DA, Plütschow A, et al. Histopathological features and their prognostic impact in nodular lymphocyte- predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG). Br J Haematol. 2014;167(2):238-242.
9.Thurner L, Hartmann S, Fadle N, et al. Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. Nat Commun. 2020;11(1):2465.
10. Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predomi- nant Hodgkin lymphoma with immunohis- tologic and clinical correlation. Am J Surg Pathol. 2003;27(10):1346-1356.
11. Hartmann S, Plütschow A, Mottok A, et al. The time to relapse correlates with the histopathological growth pattern in nodu- lar lymphocyte predominant Hodgkin lym- phoma. Am J Hematol. 2019;94(11):1208- 1213.
12. Eichenauer DA, Plütschow A, Schröder L, et al. Relapsed and refractory nodular lym- phocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132(14):1519- 1525.
13. Al-Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol.
2010;28(5):793-799.
14. Biasoli I, Stamatoullas A, Meignin V, et al.
Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2010;116(3):631-639.
15. Wickert RS, Weisenburger DD, Tierens A, Greiner TC, Chan WC. Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subse- quent large-cell lymphoma of B lineage. Blood. 1995;86(6):2312-2320.
16. Ohno T, Huang JZ, Wu G, Park KH, Weisenburger DD, Chan WC. The tumor cells in nodular lymphocyte-predominant Hodgkin disease are clonally related to the large cell lymphoma occurring in the same individual. Direct demonstration by single cell analysis. Am J Clin Pathol. 2001;116(4):506-511.
17.Pan LX, Diss TC, Peng HZ, Norton AJ, Isaacson PG. Nodular lymphocyte predom- inance Hodgkin's disease: a monoclonal or polyclonal B-cell disorder? Blood. 1996;87(6):2428-2434.
18. Bräuninger A, Yang W, Wacker HH, Rajewsky K, Küppers R, Hansmann ML. B- cell development in progressively trans- formed germinal centers: similarities and differences compared with classical germi- nal centers and lymphocyte-predominant Hodgkin disease. Blood. 2001;97(3):714- 719.
19. Hansmann ML, Fellbaum C, Hui PK, Moubayed P. Progressive transformation of germinal centers with and without associa- tion to Hodgkin's disease. Am J Clin Pathol. 1990;93(2):219-226.
20. Hartmann S, Winkelmann R, Metcalf RA, et al. Immunoarchitectural patterns of pro- gressive transformation of germinal centers with and without nodular lymphocyte-pre- dominant Hodgkin lymphoma. Hum Pathol. 2015;46(11):1655-1661.
21. Kiil K, Bein J, Schuhmacher B, et al. A high number of IgG4-positive plasma cells rules out nodular lymphocyte predominant Hodgkin lymphoma. Virchows Arch. 2018;473(6):759-764.
22. Hartmann S, Eichenauer DA. Nodular lym- phocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T- cell/histiocyte rich large B-cell lymphoma. Pathology. 2020;52(1):142-153.
23. Schliffke S, Akyüz N, Ford CT, et al. Clinical response to ibrutinib is accompa- nied by normalization of the T-cell environ- ment in CLL-related autoimmune cytope- nia. Leukemia. 2016;30(11):2232-2234.
24.Schliffke S, Sivina M, Kim E, et al. Dynamic changes of the normal B lympho- cyte repertoire in CLL in response to ibru- tinib or FCR chemo-immunotherapy. Oncoimmunology. 2018;7(4):e1417720.
25.Akyüz N, Brandt A, Stein A, et al. T-cell diversification reflects antigen selection in the blood of patients on immune check- point inhibition and may be exploited as liquid biopsy biomarker. Int J Cancer. 2017;140(11):2535-2544.
26. Oberle A, Brandt A, Voigtlaender M, et al. Monitoring multiple myeloma by next-
generation sequencing of V(D)J rearrange- ments from circulating myeloma cells and cell-free myeloma DNA. Haematologica. 2017;102(6):1105-1111.
27. Mährle T, Akyüz N, Fuchs P, et al. Deep sequencing of bone marrow microenviron- ments of patients with del(5q) myelodys- plastic syndrome reveals imprints of anti- genic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide. Haematologica. 2019;104(7): 1355-1364.
28. Schultheiss C, Paschold L, Simnica D, et al. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity. 2020;53(2): 442-455.
29. Brüggemann M, Kotrová M, Knecht H, et al. Standardized next-generation sequenc- ing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia. 2019;33(9):2241-2253.
30. Bolotin DA, Poslavsky S, Mitrophanov I, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5):380-381.
31. Giudicelli V, Chaume D, Lefranc M-P. IMGT/GENE-DB: a comprehensive data- base for human and mouse immunoglobu- lin and T cell receptor genes. Nucleic Acids Res. 2005;33(Database issue):D256-D261.
32. Nazarov VI, Pogorelyy MV, Komech EA, et al. tcR: an R package for T cell receptor repertoire advanced data analysis. BMC Bioinformatics. 2015;16(1):175.
33.Dray S, Dufour A-B. The ade4 package: implementing the duality diagram for ecol- ogists. J Stat Software. 2007;22(4):20.
34. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 2016.
35.Cheng J, Bostock M, Heer J. bubbles: d3 bubble chart htmlwidget. R package ver- sion 0.2.
36. Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4(43):1686.
37. Evans PAS, Pott C, Groenen PJTA, et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia. 2007;21(2): 207-214.
38. Bräuninger A, Küppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lym- phocyte predominant Hodgkin disease rep- resent clonal populations of germinal cen- ter-derived tumor B cells. Proc Natl Acad Sci U S A. 1997;94(17):9337-9342.
39. Liso A, Capello D, Marafioti T, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood. 2006;108(3):1013-1020.
40. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-pre- dominant Hodgkin's disease from a clonal expansion of highly mutated germinal-cen- ter B cells. N Engl J Med. 1997;337(7):453-
haematologica | 2021; 106(10)
2665